SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study

Cited by (1,002)

Items 301–400 of 1,002

1. Myopathy with statin–fibrate combination therapy: clinical considerations
   Jacobson, Terry A. · 2009 · Nature Reviews Endocrinology
2. Muscle- and skeletal-related side-effects of statins: tip of the iceberg?
   Johann Auer, Helmut F. Sinzinger, Barry Franklin, Robert Berent · 2014 · European Journal of Preventive Cardiology
3. Treatment Options for Statin-Associated Muscle Symptoms
   Ulrich Laufs, Hubert Scharnagl, Martin Halle, Eberhard Windler, Matthias Endres, Winfried März · 2015 · Deutsches Ärzteblatt international
4. The NTCP‐inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics
   Antje Blank, Annette Eidam, Mathias Haag, Nicolas Hohmann, Jürgen Burhenne, Matthias Georg Schwab, Stan F.J. van de Graaf, Markus Robert Meyer, HH Maurer, K Meier et al. · 2017 · Clinical Pharmacology & Therapeutics
5. Statin-induced necrotizing myositis – A discrete autoimmune entity within the “statin-induced myopathy spectrum”
   Philip Hamann, Robert G Cooper, Neil John McHugh, Hector Chinoy · 2013 · Autoimmunity Reviews
6. Cardiovascular pharmacogenomics and individualized drug therapy
   Pereira, Naveen L., Weinshilboum, Richard M. · 2009 · Nature Reviews Cardiology
7. Clinical Implications of Pharmacogenetic Variation on the Effects of Statins
   Simran D. S. Maggo, Martin Alexander Kennedy, David W. J. Clark · 2010 · Drug Safety
8. Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease
   Jasper Jan Brugts, Aaron J. Isaacs, Eric H. Boersma, Cock M. van Duijn, André Gerardus Uitterlinden, Willem J. Remme, Michel E. Bertrand, Toshiharu Ninomiya, Claudio Ceconi, John Philip Chalmers et al. · 2010 · European Heart Journal
9. National Lipid Association Annual Summary of Clinical Lipidology 2015
   Harold Edward Bays, Peter H. Jones, William Virgil Brown, Terry A. Jacobson · 2014 · Journal of clinical lipidology
10. Cryo-EM structures of human organic anion transporting polypeptide OATP1B1
    Ziyang Shan, Xuemei Yang, Huihui Liu, Yafei Yuan, Yuan Xiao, Jing Nan, Wei Zhang, Wenqi Song, Jufang Wang, Feiwen Wei et al. · 2023 · Cell Research
11. Intracellular Drug Concentrations
    Colin T. Dollery · 2012 · Clinical Pharmacology & Therapeutics
12. Genetic involvement in statins induced myopathy. Preliminary data from an observational case–control study
    Luca Puccetti, Federica Ciani, A. Auteri · 2010 · Atherosclerosis
13. Cardiovascular Pharmacogenomics
    Dan M. Roden, Julie A. Johnson, Stephen E. Kimmel, Ronald M. Krauss, Marisa Wong Medina, Alan R. Shuldiner, Russell A. Wilke · 2011 · Circulation Research
14. Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin‐induced lactic acidosis
    Kana Toyama, Atsushi Yonezawa, Satohiro Masuda, R Osawa, Masaya Hosokawa, Shimpei Fujimoto, Nobuya Inagaki, Ken‐ichi Inui, Toshiya Katsura · 2012 · British Journal of Pharmacology
15. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review
    William J. Canestaro, Melissa A. Austin, Kenneth E. Thummel · 2014 · Genetics in Medicine
16. Vitamin D deficiency, myositis–myalgia, and reversible statin intolerance
    Charles J. Glueck, Shaaista Budhani, Silpa S. Masineni, Cesar Abuchaibe, Naseer Khan, Ping Wang, Naila Goldenberg · 2011 · Current Medical Research and Opinion
17. Precision medicine: does ethnicity information complement genotype-based prescribing decisions?
    Rashmi R. Shah, Andrea Gaedigk · 2017 · Therapeutic Advances in Drug Safety
18. Genetic predisposition to statin myopathy
    Georgirene D. Vladutiu · 2008 · Current Opinion in Rheumatology
19. Statin myopathy: a review of recent progress
    Andrew Lee Mammen, Anthony A. Amato · 2010 · Current Opinion in Rheumatology
20. Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy
    Stringer, Henry A.J., Sohi, Gurmeet K., Maguire, John A., Côté, Hélène C.F. · 2013 · Journal of the Neurological Sciences
21. Genomewide Association Studies in Cardiovascular Disease—An Update 2011
    Tanja Zeller, Stefan Blankenberg, Patrick Diemert · 2011 · Clinical Chemistry
22. Approach to the Patient Who Is Intolerant of Statin Therapy
    Robert H. Eckel · 2010 · The Journal of Clinical Endocrinology & Metabolism
23. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort
    Michel R. Hoenig, Philip J. Walker, Christine Gurnsey, Karen Beadle, Leslie P. Johnson · 2011 · Journal of clinical lipidology
24. The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions
    Daniella Kovacsics, I. Patik, C. Özvegy-Laczka · 2017 · Expert Opinion on Drug Metabolism & Toxicology
25. Evidence-Based Management of Statin Myopathy
    Charles R. Harper, Terry A. Jacobson · 2010 · Current Atherosclerosis Reports
26. Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective
    Wei Tang, Anthony Y.H. Lu · 2009 · Drug Metabolism Reviews
27. Statin-Associated Rhabdomyolysis: Is There a Dose-Response Relationship?
    Anne Marie Holbrook, M. S. Wain Wright, Melani Sung, Christine M. Ribic, Steven K. Baker · 2011 · Canadian Journal of Cardiology
28. The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia
    Jana Vandrovcová, Ellen R. A. Thomas, Santosh S. Atanur, Penny J. Norsworthy, Clare K. Y. Neuwirth, Yvonne Tan, Dalia Kasperavičiūtė, Jennifer Biggs, Laurence Gamé, Michael Mueller et al. · 2013 · Genetics in Medicine
29. Personalized medicine: Genetic risk prediction of drug response
    Ge Zhang, Daniel W. Nebert · 2017 · Pharmacology & Therapeutics
30. Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits
    Joseph Maranville, Nancy Jean Cox · 2015 · The Pharmacogenomics Journal
31. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective
    Marc Maliepaard, Charity Nofziger, Marisa Papaluca, Issam Zineh, Yoshiaki Uyama, Krishna Prasad, Christian Grimstein, Michael A. Pacanowski, Falk Ehmann, Silvia Dossena et al. · 2013 · Nature Reviews Drug Discovery
32. Exome Sequencing Implicates an Increased Burden of Rare Potassium Channel Variants in the Risk of Drug-Induced Long QT Interval Syndrome
    Peter Weeke, Jonathan D. Mosley, David Hanna, Jessica T. Delaney, Christian M. Shaffer, Quinn Stanton Wells, Sara L. Van Driest, Jason H. Karnes, Christie Ingram, Yan Ping Guo et al. · 2014 · Journal of the American College of Cardiology
33. Hepatitis C Virus-related Cirrhosis is a Major Determinant of the Expression Levels of Hepatic Drug Transporters
    Ken Ogasawara, Tomohiro Terada, Toshiya Katsura, Etsuro Hatano, Iwao Ikai, Yoshio Yamaoka, Ken‐ichi Inui · 2010 · Drug Metabolism and Pharmacokinetics
34. Genetic Architecture of Type 2 Diabetes: Recent Progress and Clinical Implications
    Richard William Grant, Allan F. Moore, José C. Florez · 2009 · Diabetes Care
35. Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition☆
    Fan-Fan Zhou, Ling Zhu, Ke Wang, M. Murray · 2017 · Advanced Drug Delivery Reviews
36. Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1‐Related Variability in Pharmacodynamics of Rosuvastatin
    RH Rose, Sibylle Neuhoff, Khaled Abduljalil, Manoranjenni Chetty, Amin Rostami‐Hodjegan, Masoud Jamei · 2014 · CPT Pharmacometrics & Systems Pharmacology
37. The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration
    Seyed Soheil Saeedi Saravi, Seyed Sobhan Saeedi Saravi, Alireza Arefidoust, Ahmad Reza Dehpour · 2017 · Metabolic Brain Disease
38. Molecular mechanisms of statin intolerance
    Anna Gluba-Brzózka, Beata Franczyk, Peter Paul Toth, Jacek Rysz, Maciej Banach · 2016 · Archives of Medical Science
39. Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact
    Cathelijne H. van der Wouden, Paul C. D. Bank, Kübra Özokcu, Jesse Joachim Swen, Henk‐Jan Guchelaar · 2019 · Genes
40. Dealing with the complex drug–drug interactions: Towards mechanistic models
    Manthena V. S. Varma, K. Sandy Pang, Nina Isoherranen, Ping Zhao · 2014 · Biopharmaceutics & Drug Disposition
41. In vitroevidence for the role of OATP and OCT uptake transporters in drug–drug interactions
    Jürgen Kindla, Martin F. Fromm, Jörg König · 2009 · Expert Opinion on Drug Metabolism & Toxicology
42. The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era
    Marylyn DeRiggi Ritchie · 2012 · Human Genetics
43. Genetic Variation in 3-Hydroxy-3-Methylglutaryl CoA Reductase Modifies the Chemopreventive Activity of Statins for Colorectal Cancer
    Steven M. Lipkin, Elizabeth Chao, Victor Rau Moreno, Laura S. Rozek, Hedy S. Rennert, Mila Pinchev, Diana Dizon, Gad Rennert, Levy Kopelovich, Stephen B. Gruber · 2010 · Cancer Prevention Research
44. Pharmacogenomics of platinum-based chemotherapy in NSCLC
    Michelle A.T. Hildebrandt, Jian Hong Gu, Xifeng Wu · 2009 · Expert Opinion on Drug Metabolism & Toxicology
45. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes
    Andrea H. Ramirez, Christian M. Shaffer, Jessica T. Delaney, David Sexton, Shawn Levy, Mark J. Rieder, Deborah A. Nickerson, Alfred L. George, Dan M. Roden · 2012 · The Pharmacogenomics Journal
46. Pharmacogenetics of Statin-Induced Myotoxicity
    Ping Siu Kee, Paul K. L. Chin, Martin Alexander Kennedy, Simran D. S. Maggo · 2020 · Frontiers in Genetics
47. Genetic Background of Patients from a University Medical Center in Manhattan: Implications for Personalized Medicine
    Bamidele O. Tayo, Marie Teil, Liping Tong, Huaizhen Qin, Gregory Khitrov, Weijia Zhang, Quinbin Song, Omri Gottesman, Xiaofeng Zhu, Alexandre C. Pereira et al. · 2011 · PLoS ONE
48. Clinical Association Between Pharmacogenomics and Adverse Drug Reactions
    Zhi-Wei Zhou, Xiao-Wu Chen, Kevin Sneed, Yin-Xue Yang, Xueji Zhang, Zhi-Xu He, Kevin Chow, Tianxin Yang, Wei Duan, Shu-Feng Zhou · 2015 · Drugs
49. PharmGKB very important pharmacogene: SLCO1B1
    Connie M. Oshiro, Lara M. Mangravite, Teri E. Klein, Russ Biagio Altman · 2010 · Pharmacogenetics and Genomics
50. Statin Intolerance: A Literature Review and Management Strategies
    David R. Saxon, Robert H. Eckel · 2016 · Progress in Cardiovascular Diseases
51. The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics
    Ute I. Schwarz, Markus Gulilat, Richard B. Kim · 2018 · Cold Spring Harbor Perspectives in Medicine
52. Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people
    MRC/BHF Heart Protection Study Collaborative Group · 2009 · BMC Clinical Pharmacology
53. Multi-omics profiling: the way toward precision medicine in metabolic diseases
    Cheng Hu, Weiping Jia · 2021 · Journal of Molecular Cell Biology
54. Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy
    Martin H. Bluth, Jing Li · 2011 · Pharmacogenomics and Personalized Medicine
55. Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters
    Hiroyuki Kusuhara, Yuichi Sugiyama · 2010 · Drug Metabolism Reviews
56. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
    Jeffrey J. W. Verschuren, Stella Trompet, Judith A.M. Wessels, Henk‐Jan Guchelaar, Moniek P.M. de Maat, Maarten L. Simoons, J. Wouter Jukema · 2011 · European Heart Journal
57. Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity: a prospective observational cohort study
    Ashham Mansur, Maximilian Steinau, Aron‐Frederik Popov, Michael B. Ghadimi, Tim Beißbarth, Martin Bauer, José Maria Hinz · 2015 · BMC Medicine
58. Pharmacogenomics: A road ahead for precision medicine in psychiatry
    Antonio F. Pardiñas, Michael John Owen, James Walters · 2021 · Neuron
59. The Clinical Features of Myositis-Associated Autoantibodies: a Review
    Harsha Gunawardena · 2015 · Clinical Reviews in Allergy & Immunology
60. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients
    Ana Alkelai, Lior Greenbaum, Amihai Rigbi, Kyra Kanyas, Bernard Lerer · 2009 · Psychopharmacology
61. Personalized medicine: hope or hype?
    Keyan Salari, Hugh C Watkins, Euan Angus Ashley · 2012 · European Heart Journal
62. Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence
    Liam R. Brunham, Steven K. Baker, Andrew Lee Mammen, G.B. John Mancini, Robert S. Rosenson · 2018 · Cardiovascular Research
63. Genetics of Clozapine-Associated Neutropenia: Recent Advances, Challenges and Future Perspective
    Sophie E. Legge, James Walters · 2019 · Pharmacogenomics
64. Comparing low-pass sequencing and genotyping for trait mapping in pharmacogenetics
    Kaja A. Wasik, Tomaz Berisa, Joseph K. Pickrell, Jeremiah H. Li, Dana J. Fraser, Karen S. King, Charles J. Cox · 2021 · BMC Genomics
65. Effectiveness of Combination Therapy With Statin and Another Lipid-Modifying Agent Compared With Intensified Statin Monotherapy
    Kimberly Anne Gudzune, Anne Kress Monroe, Ritu Sharma, Padmini D Ranasinghe, Yohalakshmi Chelladurai, Karen A. Robinson · 2014 · Annals of Internal Medicine
66. Clinical Application of Cardiovascular Pharmacogenetics
    Deepak Voora, Geoffrey S. Ginsburg · 2012 · Journal of the American College of Cardiology
67. Individualising the risks of statins in men and women in England and Wales: population-based cohort study
    Julia Hippisley‐Cox, Carol A. C. Coupland · 2010 · Heart
68. The spectrum of statin myopathy
    Payam Mohassel, Andrew Lee Mammen · 2013 · Current Opinion in Rheumatology
69. Clinical response to statins: Mechanism(s) of variable activity and adverse effects
    Cesare Riccardo Sirtori, Giuliana Germana Mombelli, Michela Triolo, Reijo Laaksonen · 2011 · Annals of Medicine
70. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia
    Paulo Caleb Júnior Lima Santos, Ana Carolina Moron Gagliardi, Marcio Hiroshi Miname, Ana Paula Marte Chacra, Raul Dias Santos, José Eduardo Krieger, Alexandre C. Pereira · 2011 · European Journal of Clinical Pharmacology
71. Pharmacogenomics: a systems approach
    Liewei Wang · 2009 · WIREs Systems Biology and Medicine
72. Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population-Modeling Approach
    Tsamandouras, N, Dickinson, G, Guo, Y, Hall, S, Rostami-Hodjegan, A, Galetin, A, Aarons, L · 2014 · Clinical Pharmacology & Therapeutics
73. Immune-mediated necrotising myopathy: A critical review of current concepts
    Jessica Alice Day, Vidya Sadanand Limaye · 2019 · Seminars in Arthritis and Rheumatism
74. Statins for Primary Prevention in Older Adults—Moving Toward Evidence‐Based Decision‐Making
    Sonal Singh, Susan J. Zieman, Alan S. Go, Stephen P. Fortmann, NANETTE KASS WENGER, Jerome L. Fleg, Barbara Radziszewska, Neil J. Stone, Sophia Zoungas, Jerry H. Gurwitz · 2018 · Journal of the American Geriatrics Society
75. From pharmacogenetics to pharmaco-omics: Milestones and future directions
    Chiara Auwerx, Marie C. Sadler, Alexandre Reymond, Zoltán Kutalik · 2022 · Human Genetics and Genomics Advances
76. Treating statin-intolerant patients
    Marcello Arca, Pigna · 2011 · Diabetes Metabolic Syndrome and Obesity
77. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality
    Evangelos N. Liberopoulos, Matilda Florentin, Dimitri P. Mikhailidis, Moses Elisaf · 2008 · Expert Opinion on Drug Safety
78. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D
    Shaunna L. Clark, Daniel E. Adkins, Karolina A. Åberg, John M. Hettema, Joseph L. McClay, Renan Pedra de Souza, Edwin J. C. G. van den Oord · 2011 · Psychological Medicine
79. Genome Wide Analysis of Drug-Induced Torsades de Pointes: Lack of Common Variants with Large Effect Sizes
    Elijah Raphael Behr, Marylyn DeRiggi Ritchie, Toshihiro Tanaka, Stefan Kääb, Dana C. Crawford, Paola Nicoletti, Aris Floratos, Moritz F. Sinner, Prince J. Kannankeril, Arthur A.M. Wilde et al. · 2013 · PLoS ONE
80. Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology
    Lando Janssen, Neeltje A. E. Allard, Christiaan G. J. Saris, Jaap Keijer, Maria T. E. Hopman, Silvie Timmers · 2019 · Physiological Reviews
81. Pharmacogenetics of Adverse Drug Reactions
    Orod Osanlou, Munir Pirmohamed, Ann K. Daly · 2018 · Advances in pharmacology
82. Gender Is an Important Determinant of the Disposition of the Loop Diuretic Torasemide
    Ulrike Werner, Dierk Werner, Svetlana Heinbüchner, Bernhard Graf, Hüseyin İnce, Stefan Kische, Petra Thürmann, Jörg König, Martin F. Fromm, Oliver Zolk · 2009 · The Journal of Clinical Pharmacology
83. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2
    Marco Ferrari, Luigina Guasti, Andrea Maria Maresca, Mauro Mirabile, Sara Contini, Anna Maria Grandi, Franca Marino, Marco Cosentino · 2014 · European Journal of Clinical Pharmacology
84. Individualized Risk for Statin-Induced Myopathy: Current Knowledge, Emerging Challenges and Potential Solutions
    QiPing Feng, Russell A. Wilke, Tesfaye Mersha Baye · 2012 · Pharmacogenomics
85. Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk
    Qingtao Hou, Sheyu Li, Ling Li, Yun Li, Xin Sun, Haoming Tian · 2015 · Medicine
86. Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review
    Renske G Kamperman, Anneke J. van der Kooi, Marianne de Visser, Eleonora Aronica, Joost Raaphorst · 2022 · International Journal of Molecular Sciences
87. Chapter 7: Pharmacogenomics
    Konrad J. Karczewski, Roxana Daneshjou, Russ Biagio Altman · 2012 · PLoS Computational Biology
88. Role of genomics on the path to personalized medicine
    Johanne Tremblay, Pavel Hamet · 2012 · Metabolism
89. Efflux and uptake transporters as determinants of statin response
    Rodrigues, Alice C · 2010 · Expert Opinion on Drug Metabolism & Toxicology
90. Mechanisms of statin-induced myalgia assessed by physiogenomic associations
    Ruaño, Gualberto, Windemuth, Andreas, Wu, Alan H.B., Kane, John P., Malloy, Mary J., Pullinger, Clive R., Kocherla, Mohan, Bogaard, Kali, Gordon, Bruce R., Holford, Theodore R. et al. · 2011 · Atherosclerosis
91. The genetics of coronary heart disease
    Daniel I. Swerdlow, Michael Vaclav Holmes, Seamus C. Harrison, Steve Eric Humphries · 2012 · British Medical Bulletin
92. Pharmacogenomics for Primary Care: An Overview
    Victoria Rollinson, Richard Myles Turner, Munir Pirmohamed · 2020 · Genes
93. Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia
    Paulo Caleb Júnior Lima Santos, Aline Morgan Alvarenga, Cinthia Elim Jannes, Luciana Turolla, José Eduardo Krieger, Raul Dias Santos, Alexandre C. Pereira · 2014 · Atherosclerosis
94. Drug–drug interactions with statins: will pitavastatin overcome the statins’ Achilles’ heel?
    Alberto Corsini, R Češka · 2011 · Current Medical Research and Opinion
95. Statins and skeletal muscles toxicity: From clinical trials to everyday practice
    Giuseppe Danilo Norata, Gianpaolo Tibolla, Alberico Luigi Catapano · 2014 · Pharmacological Research
96. Genomic Association Analysis Identifies Multiple Loci Influencing Antihypertensive Response to an Angiotensin II Receptor Blocker
    Stephen T. Turner, Kent R. Bailey, Gary L. Schwartz, Arlene B. Chapman, High Seng Chai, Eric Boerwinkle · 2012 · Hypertension
97. An overview of statin-induced myopathy and perspectives for the future
    Dragana Nikolić, Maciej Banach, Roberta Chianetta, Luca Marco Luzzu, Anca Pantea Stoian, Camelia Cristina Diaconu, Roberto Citarrella, Giuseppe Montalto, Manfredi Rizzo · 2020 · Expert Opinion on Drug Safety
98. Lipoproteins in chronic kidney disease: from bench to bedside
    Thimoteus Speer, Paul M. Ridker, Arnold von Eckardstein, Stefan J. Schunk, Danilo Fliser · 2020 · European Heart Journal
99. Genetics of Cardiovascular Disease: How Far Are We from Personalized CVD Risk Prediction and Management?
    Michal Vrablı́k, Dana Dlouhá, Veronika Todorovová, Dénes Stefler, Jaroslav Alois Hubacek · 2021 · International Journal of Molecular Sciences
100. Transporters, Trojan horses and therapeutics: suitability of bile acid and peptide transporters for drug delivery
     Werner Kramer · 2011 · Biological Chemistry